[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343006-105":59,"doc-detail-343006-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","survival-difference-of-endometrial-cancer-patients-with-peritoneal-metastasis-receiving-cytoreductive-surgery-crs-with-and-without-hyperthermic-intraperitoneal-chemotherapy-hipec-a-systematic-review-and-meta-analysis","Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Systematic Review and Meta-Analysis","","Although multiple studies evaluated cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in endometrial cancer with peritoneal metastasis (ECPM), no direct comparison had previously been undertaken. A meta-analysis compared overall survival associated with CRS plus HIPEC versus CRS alone, using 21 studies (1116 cases) and 10 studies (152 cases). Across all articles, 1-year survival was higher with CRS+HIPEC (82.28% vs 64.68%; p=0.0102), as was 2-year survival (56.07% vs 36.95%; p=0.0014), but 5-year survival showed no significant difference. HIPEC addition improved early outcomes, particularly within the first two years.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-difference-of-endometrial-cancer-patients-with-peritoneal-metastasis-receiving-cytoreductive-surgery-crs-with-and-without-hyperthermic-intraperitoneal-chemotherapy-hipec-a-systematic-review-and-meta-analysis/343006/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-difference-of-endometrial-cancer-patients-with-peritoneal-metastasis-receiving-cytoreductive-surgery-crs-with-and-without-hyperthermic-intraperitoneal-chemotherapy-hipec-a-systematic-review-and-meta-analysis/343006.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the meta-analysis address?","Question",{"text":112,"@type":113},"Whether CRS plus HIPEC provides additional survival benefits compared with CRS alone for endometrial cancer patients with peritoneal metastasis (ECPM).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many studies and cases were included for each treatment group?",{"text":117,"@type":113},"The analysis included 21 studies (1116 cases) for CRS only and 10 studies (152 cases) for CRS plus HIPEC.",{"name":119,"@type":110,"acceptedAnswer":120},"Did adding HIPEC improve 1-year, 2-year, and 5-year survival?",{"text":121,"@type":113},"Yes for 1-year and 2-year survival, with higher rates for CRS+HIPEC; however, 5-year survival did not show a statistically significant difference.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343006,1790468710,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \n# Survival Difference of Endometrial Cancer Patients with\n\nPeritoneal Metastasis Receiving Cytoreductive Surgery (CRS)with and without Hyperthermic Intraperitoneal Chemotherapy(HIPEC): A Systematic Review and Meta-Analysis  \nIvan Panczel1, Miklos Acs 2, Magdolna Herold1,3 , Viktor Madar-Dank4, Pompiliu Piso 5, Hans Jürgen Schlitt 2,Magdolna Dank 1, Attila Marcell Szasz 1,*,† and Zoltan Herold 1,†  \nCitation: Panczel, I.; Acs, M.; Herold,M.; Madar-Dank, V.; Piso, P.; Schlitt,H.J.; Dank, M.; Szasz, A.M.; Herold, Z.Survival Difference of EndometrialCancer Patients with PeritonealMetastasis Receiving CytoreductiveSurgery (CRS) with and withoutHyperthermic IntraperitonealChemotherapy (HIPEC): A Systematic  \nReview and Meta-Analysis. Int. J. Mol.Sci. 2024, 25, 7495 . https://doi.org/10.3390/ijms25137495  \nAcademic Editor: Valentina De Falco  \nReceived: 11 June 2024  \nRevised: 4 July 2024  \nAccepted: 6 July 2024  \nPublished: 8 July 2024  \nCopyright: © 2024 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/  \n4.0/) .  \n1 Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University,H-1083 Budapest, Hungary; ivan.panczel@gmail.com (I.P.)  \n2 Department of Surgery, University Medical Center Regensburg, D-93053 Regensburg, Germany  \n3 Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary  \n4 Department of Finance, Rutgers University, Newark, NJ 07102, USA  \n5 Department of General and Visceral Surgery, Hospital Barmherzige Brüder, D-93049 Regensburg, Germany  \n* Correspondence: szasz.attila.marcell@semmelweis.hu; Tel.: +36-1-459-1500† Szasz, A.M. and Herold, Z. share senior authorship.  \nAbstract: Although several studies have been completed to investigate the effect of cytoreductivesurgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in endometrialcancer with peritoneal metastasis (ECPM), a direct comparison was not performed previously. A meta-analysis was performed to investigate the suspected additional survival benefits of CRS plus HIPECover CRS only. Twenty-one and ten studies with a total number of 1116 and 152 cases investigatingCRS only and CRS plus HIPEC were identified, respectively. When all articles were analyzed, the1-year survival rate was 17.60% higher for CRS plus HIPEC (82.28% vs. 64.68%; p = 0.0102) . Thesame tendency was observed forthe 2-year (56.07% vs. 36.95%; difference: 19.12%; p = 0.0014), butnot forthe 5-year (21.88% vs. 16.45%; difference: 5.43%; p = 0.3918) survival rates. The same clinicalsignificance, but statistically less strong observations, could be made if only the studies publishedafter 2010 were investigated (1-year survival rate: 12.08% and p = 0.0648; 2-year survival rate: 10.90%and p = 0.0988) . CRS remains one of the core elements of ECPM treatment, but the addition of HIPECto CRS can increase the positive clinical outcome, especially in the first 2 years.  \nKeywords: cytoreduction surgical procedures; endometrial neoplasms; hyperthermic intraperitonealchemotherapy; peritoneal metastasis  \n## 1. Introduction\n\nEndometrial cancer isthe second most common gynecological cancer globally [1] .In the US, more than 60,000 newly diagnosed cases are registered annually [2] . A peakin the incidence of the disease is seen in those between the ages of 60 and 70, and thereis a known strong correlation with obesity [3] . Histologically, more than 90 percent ofuterine malignancies are of the endometrial type and originate from the epithelial layer.The remainder originate from mesenchymal cells and derive from themyometrial layer orthe endometrial stroma [4] . The diagnosis of endometrial cancer in the early stage is usuallyfavorable, with an overall 5-year survival rate of 85–95%, but the recurrence rate is veryhigh (~10–15%) [5,6] . On the","cbCaibnpexSkFHTN","https://ap.wps.com/l/cbCaibnpexSkFHTN","pdf",3162751,18,"English","# 1. Introduction\n# Abstract\n# Keywords","[{\"question\":\"What clinical question does the meta-analysis address?\",\"answer\":\"Whether CRS plus HIPEC provides additional survival benefits compared with CRS alone for endometrial cancer patients with peritoneal metastasis (ECPM).\"},{\"question\":\"How many studies and cases were included for each treatment group?\",\"answer\":\"The analysis included 21 studies (1116 cases) for CRS only and 10 studies (152 cases) for CRS plus HIPEC.\"},{\"question\":\"Did adding HIPEC improve 1-year, 2-year, and 5-year survival?\",\"answer\":\"Yes for 1-year and 2-year survival, with higher rates for CRS+HIPEC; however, 5-year survival did not show a statistically significant difference.\"}]","Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Systematic Review and Meta-Analysis | PDF",1790049363,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cbce1e8a94a3d75ac974948d5f3fd61.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d07858c7550965215cd61289d92cade.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db31f83535f67afd4b8a7d548e44ed23.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57f838afed4775508ed26575d013c431.webp",980,1385]